Liang et al. demonstrated that the depletion of interferon regulatory factor 1 encoded by the IRF1 gene increased the efficacy of bevacizumab (anti-VEGF-A) treatment in a glioma xenograft model through enhanced apoptosis-inducing factor-dependent apoptosis [12]. The gene discussed is IRF1; the disease is central nervous system cancer.